1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Prostate cancer

Prostate cancer: diagnosis and management

NICE guideline [NG131] Published: 09 May 2019

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Evidence

Review and download supporting evidence. Includes the full guideline if available.

Supporting evidence

  • Surveillance report  
  • 2021 exceptional surveillance of prostate cancer: diagnosis and management (NICE guideline NG131)  
  • Economic analysis  
  • Health economic model report PDF 10.35 MB 20 May 2019  
  • Evidence review  
  • Evidence reviews – May 2019  
  • A: Bisphosphonates PDF 1.56 MB 09 May 2019  
  • B: Docetaxel in people with hormone-sensitive prostate cancer PDF 971 KB 09 May 2019  
  • C: Radical radiotherapy PDF 1.44 MB 09 May 2019  
  • D: Diagnosing and identifying clinically significant prostate cancer PDF 2.77 MB 09 May 2019  
  • E: Following up people at increased risk of prostate cancer PDF 4.15 MB 09 May 2019  
  • F: Identifying prostate cancer clinical progression in people with low- to intermediate-risk cancer PDF 1.25 MB 09 May 2019  
  • G: Active surveillance, radical prostatectomy or radical radiotherapy in people with localised prostate cancer PDF 4.88 MB 09 May 2019  
  • H: Follow-up protocols after radical treatment PDF 1.03 MB 09 May 2019  
  • Full guidance  
  • Full guideline – January 2014  
  • Full guideline PDF 4.7 MB 08 January 2014